Back

Regenerative human liver organoids (HLOs) in a pillar/perfusion plate for hepatotoxicity assays

Shrestha, S.; Acharya, P.; Kang, S.-Y.; Vanga, M. G.; Lekkala, V. K. R.; Liu, J.; Yang, Y.; Joshi, P.; Lee, M.-Y.

2024-03-29 bioengineering
10.1101/2024.03.25.586638 bioRxiv
Show abstract

Human liver organoids (HLOs) differentiated from embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and adult stem cells (ASCs) can recapitulate the structure and function of human fetal liver tissues, thus being considered as a promising tissue model for liver diseases and predictive compound screening. However, the adoption of HLOs in drug discovery faces several technical challenges, which include the lengthy differentiation process with multiple culture media leading to batch-to-batch variation, short-term maintenance of hepatic functions post-maturation, low assay throughput due to Matrigel dissociation and HLO transfer to a microtiter well plate, and insufficient maturity levels compared to primary hepatocytes. To address these issues, expandable HLOs (Exp-HLOs) derived from human iPSCs were generated by optimizing differentiation protocols, which were rapidly printed on a 144-pillar plate with sidewalls and slits (144PillarPlate) and dynamically cultured for up to 20 days into differentiated HLOs (Diff-HLOs) in a 144-perfusion plate with perfusion wells and reservoirs (144PerfusionPlate) for in situ organoid culture and analysis. The dynamically cultured Diff-HLOs exhibited greater maturity and reproducibility than those cultured statically, especially after a 10-day differentiation period. In addition, Diff-HLOs in the pillar/perfusion plate were tested with acetaminophen and troglitazone for 3 days to assess drug-induced liver injury (DILI) and then incubated in an expansion medium for 10 days to evaluate liver recovery from DILI. The assessment of liver regeneration post-injury is critical to understanding the mechanism of recovery and determining the threshold drug concentration beyond which there will be a sharp decrease in the livers regenerative capacity. We envision that bioprinted Diff-HLOs in the pillar/perfusion plate could be used for high-throughput screening (HTS) of hepatotoxic compounds due to the short-term differentiation of passage-able Exp-HLOs, stable hepatic function post-maturation, high reproducibility, and high throughput with capability of in situ organoid culture, testing, staining, imaging, and analysis. Graphical abstractThe overall process of dynamic liver organoid culture and in situ analysis in the 144PillarPlate/144PerfusionPlate for high-throughput hepatotoxicity assays. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=56 SRC="FIGDIR/small/586638v3_ufig1.gif" ALT="Figure 1"> View larger version (19K): org.highwire.dtl.DTLVardef@1f2902aorg.highwire.dtl.DTLVardef@1d6e074org.highwire.dtl.DTLVardef@2a0dc0org.highwire.dtl.DTLVardef@eccde0_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Stem Cell Research & Therapy
30 papers in training set
Top 0.1%
22.2%
2
Biofabrication
36 papers in training set
Top 0.1%
12.8%
3
Biomaterials
84 papers in training set
Top 0.2%
6.8%
4
Scientific Reports
3612 papers in training set
Top 23%
4.4%
5
PLOS ONE
5266 papers in training set
Top 34%
4.1%
50% of probability mass above
6
Cytotherapy
15 papers in training set
Top 0.1%
4.1%
7
Advanced Healthcare Materials
85 papers in training set
Top 0.6%
3.3%
8
Biomedicine & Pharmacotherapy
42 papers in training set
Top 0.4%
2.1%
9
Advanced Science
286 papers in training set
Top 4%
1.9%
10
Advanced Biology
29 papers in training set
Top 0.2%
1.8%
11
Biotechnology and Bioengineering
53 papers in training set
Top 0.5%
1.7%
12
Stem Cells Translational Medicine
13 papers in training set
Top 0.2%
1.5%
13
Bioactive Materials
20 papers in training set
Top 0.4%
1.5%
14
Stem Cell Reports
130 papers in training set
Top 1%
1.4%
15
International Journal of Molecular Sciences
494 papers in training set
Top 10%
1.4%
16
Hepatology Communications
22 papers in training set
Top 0.3%
1.1%
17
eLife
5828 papers in training set
Top 56%
1.1%
18
Frontiers in Bioengineering and Biotechnology
98 papers in training set
Top 2%
1.1%
19
The FASEB Journal
194 papers in training set
Top 4%
1.1%
20
Gastro Hep Advances
11 papers in training set
Top 0.2%
1.1%
21
Lab on a Chip
96 papers in training set
Top 0.9%
1.0%
22
Nature Communications
5641 papers in training set
Top 56%
0.9%
23
Cells
249 papers in training set
Top 7%
0.9%
24
Biotechnology Journal
11 papers in training set
Top 0.2%
0.9%
25
Biomaterials Advances
22 papers in training set
Top 0.6%
0.9%
26
iScience
1154 papers in training set
Top 39%
0.6%
27
Communications Biology
993 papers in training set
Top 34%
0.6%